Sermorelin vs CJC-1295: Short-Acting vs Long-Acting GHRH Analogs

What are GHRH analogs?

GHRH (growth hormone-releasing hormone) is the primary natural hypothalamic hormone that stimulates growth hormone (GH) release from the anterior pituitary. GHRH analogs are synthetic peptides designed to mimic GHRH's action on the pituitary GHRH receptor, thereby stimulating natural, endogenous GH secretion.

Sermorelin and CJC-1295 are both GHRH analogs, but they differ in: - Half-life (how long they persist in the body) - Dosing frequency (how often they need to be injected) - Duration of GH stimulation (how long the GH elevation lasts per dose) - Development and approval status (sermorelin is FDA-approved; CJC-1295 is not)

Advantage of GHRH analogs over other GH secretagogues:

GHRH analogs provide the most physiologically integrated growth hormone stimulation because GHRH is the primary natural stimulus. This contrasts with: - GHRPs (GH-releasing peptides like ipamorelin) — activate an artificial pathway - Ghrelin mimetics (like MK-677) — mimic a hormone with multiple systemic effects - Recombinant hGH — directly injected hormone, bypassing natural regulation

GHRH analogs thus provide a more "natural" approach to GH optimization, working through the body's native physiologic pathway.

Sermorelin (Geotropin) structure:

- Sequence: GH-RH 1-29 (first 29 amino acids of native GHRH) - Source: Synthetic GHRH analog - Half-life: Approximately 10 minutes in circulation - Formulation: Injectable powder reconstituted with sterile water; delivered as a solution - Dosing: Requires frequent injection (typically 1-3 times daily, 500 mcg to 2 mg per injection)

CJC-1295 structure:

CJC-1295 without DAC: - Sequence: Modified GHRH analog (30 amino acids, slightly different from sermorelin) - Half-life: Approximately 30 minutes - Formulation: Lyophilized (freeze-dried) powder, reconstituted before injection - Dosing: Requires frequent injection (1-3 times daily, similar frequency to sermorelin)

CJC-1295 with DAC (Drug Affinity Complex): - Sequence: Same GHRH analog + albumen-binding domain modification - Mechanism: The DAC modification allows the peptide to bind to serum albumin, greatly extending half-life - Half-life: Extended to approximately 6-8 days (compared to 30 minutes without DAC) - Formulation: Lyophilized powder, reconstituted before injection - Dosing: Requires infrequent injection (1-2 times per week, 100-300 mcg per injection)

Structural/pharmacokinetic comparison:

- Sermorelin: Native GHRH sequence, short half-life, frequent dosing - CJC-1295 without DAC: Modified GHRH sequence, short-to-moderate half-life, frequent dosing - CJC-1295 with DAC: Modified GHRH + albumin-binding, long half-life, infrequent dosing

The key innovation is DAC (albumin-binding), which transforms CJC-1295 from a frequent-dosing peptide to a long-acting peptide.

Sermorelin (10-minute half-life):

- Onset: 15-30 minutes after injection - Peak GH elevation: 30-60 minutes - Duration of GH elevation: 2-4 hours - Return to baseline: 4-6 hours after injection - Dosing needed: 1-3 times daily to maintain sustained GH stimulation - Convenience: Low — requires multiple daily injections - Physiologic pattern: Approximates natural GH secretion pattern (pulsatile, with intervals of low GH between pulses)

CJC-1295 without DAC (30-minute half-life):

- Onset: 15-30 minutes after injection - Peak GH elevation: 30-60 minutes - Duration of GH elevation: 2-6 hours - Return to baseline: 6-8 hours after injection - Dosing needed: 2-3 times daily to maintain sustained GH stimulation - Convenience: Low — requires multiple daily injections (similar to sermorelin) - Physiologic pattern: Similar pulsatile pattern to sermorelin

CJC-1295 with DAC (6-8 day half-life):

- Onset: 2-4 hours after injection - Peak GH elevation: 4-8 hours - Duration of GH elevation: Extended across many hours due to long half-life - Return to baseline: Gradual over several days; baseline GH remains elevated between doses - Dosing needed: 1-2 times per week (major advantage) - Convenience: High — far fewer injections needed - Physiologic pattern: More continuous GH elevation between doses; less pulsatile than sermorelin or CJC-1295 without DAC

Trade-off between half-life and physiologic pattern:

- Sermorelin: Most pulsatile (most physiologic), but inconvenient (frequent dosing) - CJC-1295 without DAC: Pulsatile, but still inconvenient (frequent dosing) - CJC-1295 with DAC: Convenient (infrequent dosing), but less pulsatile (more sustained GH elevation)

Clinical question: Is pulsatile GH stimulation superior to sustained stimulation? Evidence suggests pulsatile GH is more physiologic and may be preferable, but the clinical difference is uncertain. Some practitioners argue CJC-1295 with DAC's convenience outweighs the loss of pulsatility.

Sermorelin evidence:

- FDA-approved in 1997 (brand name Geotropin) for growth hormone deficiency in children and adults - FDA approval based on: Multiple Phase 2/3 clinical trials in GH-deficient populations - Published evidence: Extensive; 20+ published trials demonstrating efficacy in GH deficiency and some data on anti-aging and body composition - Long-term safety: 25+ years of post-market clinical experience (before market withdrawal in 2008) - Mechanism: Well-characterized, FDA-validated - Gold standard: Among the most evidence-based growth hormone secretagogues

Evidence quality: Highest — FDA-approved with extensive clinical evidence.

CJC-1295 evidence:

- Not FDA-approved for any indication - Investigational status: Developed as a research peptide by ConjuChem - Published evidence: Approximately 5-10 published human trials, mostly small (n<100) - FDA trials: CJC-1295 went through limited FDA Phase 1/2 trials but was never advanced to Phase 3 - Current use: Primarily available through compounding pharmacies; used off-label - Long-term safety: Limited data; most published studies are short-term (8-16 weeks)

Evidence quality: Moderate — mechanistically sound, some published evidence, but less extensive than sermorelin.

Comparative evidence:

Sermorelin has substantially more published evidence and FDA approval. CJC-1295 is newer, less established, but mechanistically sound. If evidence is a priority, sermorelin is superior.

Sermorelin regulatory status:

- FDA-approved: Yes (1997-2008 as Geotropin) - Market status: Withdrawn from market by Serono in 2008 (business decision, not safety concerns) - Current legal status: Legal to prescribe off-label; legal to compound by licensed pharmacies under section 503A - Availability: Available through compounding pharmacies; most familiar to pharmacists because of FDA history - Quality: Pharmaceutical-grade, reliable - Cost: Approximately $150-300/month for compounded sermorelin

CJC-1295 regulatory status:

- FDA-approved: No - Investigational status: Never completed FDA approval process - Current legal status: Legal to prescribe off-label; legal to compound under section 503A - Availability: Available through compounding pharmacies, online peptide suppliers - Post-2026 status: Expected to return to Category 1, ensuring continued compounding access - Quality: Compounding pharmacy versions are generally reliable; online sources variable - Cost: Approximately $200-400/month for compounded CJC-1295 (slightly higher than sermorelin due to extended half-life allowing lower total monthly dosing)

Practical access:

Both are available through compounding pharmacies. Sermorelin may be easier to source because it has FDA recognition. CJC-1295 is increasingly accessible, especially post-2026 reclassification.

Choose Sermorelin if:

- You prioritize strongest evidence and FDA approval history (FDA-approved, 25+ years clinical use) - You want pulsatile GH stimulation (most physiologic pattern) - You value regulatory validation and recognized pharmaceutical history - You are comfortable with multiple daily injections (1-3 times daily) - You want the most evidence-based GHRH analog - Cost is important (slightly cheaper than CJC-1295 with DAC)

Choose CJC-1295 with DAC if:

- You prioritize convenience (1-2 injections per week vs multiple daily) - You accept less extensive clinical evidence (investigational but mechanistically sound) - You prefer sustained GH elevation over pulsatile stimulation - You are willing to inject less frequently and value injection burden reduction - You want the newest, most advanced GHRH analog

Avoid CJC-1295 without DAC:

There is no advantage to CJC-1295 without DAC compared to sermorelin — it has similar frequent dosing without the FDA approval history or evidence base.

Combined use:

Some practitioners combine sermorelin + CJC-1295 with DAC for synergistic GH stimulation, though published evidence is lacking. This would increase cost and injection frequency.

Important caveats:

- Neither is FDA-approved for anti-aging or performance enhancement - Both produce modest GH elevation compared to pharmacologic hGH injection - Evidence for anti-aging benefits is lacking; use remains investigational and off-label - Long-term safety beyond 1 year is not extensively studied for CJC-1295

Bottom line:

For evidence-based practice with strongest regulatory support, choose sermorelin. For convenience with acceptable evidence, choose CJC-1295 with DAC. Both are legitimate GHRH analogs; the choice depends on whether you prioritize evidence/physiologic pulsatility (sermorelin) or convenience (CJC-1295 with DAC).